Key Takeaways
- RenovoRx’s PanTheR study evaluates the RenovoCath device’s long-term safety and effectiveness in treating solid tumors through real-world data collection.
- The University of Vermont Cancer Center is the first site to enroll patients, with more sites expected by September 2025.
- Targeted drug delivery systems aim to improve therapeutic efficacy and reduce systemic toxicity by delivering drugs directly to tumor sites.
- Advances in catheter-based systems and imaging enhance the precision and adaptability of targeted drug delivery across various cancers.
- Registry studies like PanTheR are crucial for understanding device performance in diverse populations and treatment settings.